header
Image from OpenLibrary

Optimization of the formulation of oral delivery system for improved bioavailability of an antiplatelet drug / Reham Abdelmaksoud Zayed ; Supervised Ahmed Hassen Elshafeey , Ibrahim Elsayed Mohammed , Marwa Hassan Shukr

By: Contributor(s): Material type: TextTextLanguage: English Publication details: Cairo : Reham Abdelmaksoud Zayed , 2020Description: 126 P. : charts , facsimiles ; 25cmOther title:
  • تعظيم صياغة دواء فموى مضاد للصفائح الدموية بهدف تحسين اتاحته الحيوية [Added title page title]
Subject(s): Available additional physical forms:
  • Issued also as CD
Dissertation note: Thesis (Ph.D.) - Cairo University - Faculty of Pharmacy - Department of Pharmaceutics Summary: Ticagrelor (TR) is an antiplatelet drug classified as a P2Y12 receptor antagonist. It is indicated for the prevention of thrombotic events as stroke or heart attack in patients with acute coronary syndrome(ACS) or myocardial infarction with ST-elevation. TR has one active metabolite, which has pharmacokinetics that is very similar to the parent compound.Therefore, TR has a more rapid onset and more pronounced platelet inhibition than other antiplatelet agents.TR is a class IV drug according to the biopharmaceutics classification system (BCS) with absolute bioavailability of 36% which is considered as an obstacle in oral drug delivery. It has poor solubility and permeability. Moreover, it is a substrate to P-glycoprotein (P-gp) which increases its efflux and decreases its systemic existence.This results in administrating frequent drug dosing (twice daily), that increases side effects, toxicity and decreases patient compliance.The objective of this study was to enhance the bioavailability of TR. The study is based on the preparation of oral lipid-based nanovesicles capable of increasing TR dissolution and permeability using two lipids, glyceryl monooleate (GMO) and sucrose acetate isobutyrate (SAIB) in a final tablet form as a comparative study
Tags from this library: No tags from this library for this title. Log in to add tags.
Star ratings
    Average rating: 0.0 (0 votes)
Holdings
Item type Current library Home library Call number Copy number Status Barcode
Thesis Thesis قاعة الرسائل الجامعية - الدور الاول المكتبة المركزبة الجديدة - جامعة القاهرة Cai01.08.08.Ph.D.2020.Re.O (Browse shelf(Opens below)) Not for loan 01010110082201000
CD - Rom CD - Rom مخـــزن الرســائل الجـــامعية - البدروم المكتبة المركزبة الجديدة - جامعة القاهرة Cai01.08.08.Ph.D.2020.Re.O (Browse shelf(Opens below)) 82201.CD Not for loan 01020110082201000

Thesis (Ph.D.) - Cairo University - Faculty of Pharmacy - Department of Pharmaceutics

Ticagrelor (TR) is an antiplatelet drug classified as a P2Y12 receptor antagonist. It is indicated for the prevention of thrombotic events as stroke or heart attack in patients with acute coronary syndrome(ACS) or myocardial infarction with ST-elevation. TR has one active metabolite, which has pharmacokinetics that is very similar to the parent compound.Therefore, TR has a more rapid onset and more pronounced platelet inhibition than other antiplatelet agents.TR is a class IV drug according to the biopharmaceutics classification system (BCS) with absolute bioavailability of 36% which is considered as an obstacle in oral drug delivery. It has poor solubility and permeability. Moreover, it is a substrate to P-glycoprotein (P-gp) which increases its efflux and decreases its systemic existence.This results in administrating frequent drug dosing (twice daily), that increases side effects, toxicity and decreases patient compliance.The objective of this study was to enhance the bioavailability of TR. The study is based on the preparation of oral lipid-based nanovesicles capable of increasing TR dissolution and permeability using two lipids, glyceryl monooleate (GMO) and sucrose acetate isobutyrate (SAIB) in a final tablet form as a comparative study

Issued also as CD

There are no comments on this title.

to post a comment.